Sertraline Hydrochloride (Sertraline Hcl) Capsules are indicated for the treatment of Major Depressive Disorder (MDD) in adults, Obsessive-Compulsive Disorder (OCD) in adults and pediatric patients 6 years and older. It functions as a selective serotonin reuptake inhibitor (SSRI) by potentiating serotonergic activity in the central nervous system through inhibition of neuronal reuptake of serotonin (5-HT).
Pharmacological Properties and Metabolism
The drug has weak effects on norepinephrine and dopamine reuptake. At high doses, sertraline’s effect on the QTc interval was observed, with a mean ΔΔQTc of 10 ms at approximately 2-fold the maximum recommended daily dose. The length of the QTc interval was positively correlated with serum concentrations. Sertraline undergoes extensive first-pass metabolism. Following a single 150 mg dose, peak plasma concentrations occur between 4.5 to 8.4 hours with a terminal elimination half-life of approximately 26 hours.
Clinical Trial Results
Clinical studies, including an 8-week study (MDD-1) and a 6-week study (MDD-2), demonstrated sertraline’s superiority to placebo in reducing depressive symptoms as measured by the Hamilton Rating Scale for Depression (HAMD-17) and Clinical Global Impression Severity (CGI-S) scores. A 44-week study (MDD-3) showed a significantly lower relapse rate in patients taking **sertraline** compared to placebo. The recommended dosage is 150 mg or 200 mg once daily, with a maximum of 200 mg.